These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 12664688)

  • 21. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy.
    Speer R; Wulfkuhle J; Espina V; Aurajo R; Edmiston KH; Liotta LA; Petricoin EF
    Cancer Genomics Proteomics; 2007; 4(3):157-64. PubMed ID: 17878519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer biomarker profiling with microRNAs.
    Jeffrey SS
    Nat Biotechnol; 2008 Apr; 26(4):400-1. PubMed ID: 18392022
    [No Abstract]   [Full Text] [Related]  

  • 23. [DNA microarrays for gene expression profiling of breast cancer: principles and prognostic applications].
    Bertucci F; Viens P; Birnbaum D
    Pathol Biol (Paris); 2006 Feb; 54(1):49-54. PubMed ID: 16376179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of biochips: from diagnostics to personalized medicine.
    Jain KK
    Curr Opin Drug Discov Devel; 2004 May; 7(3):285-9. PubMed ID: 15216931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microarray: an instrument for cancer surgeons of the future?
    Broadhead ML; Clark JC; Dass CR; Choong PF
    ANZ J Surg; 2010; 80(7-8):531-6. PubMed ID: 20795968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic microarrays in cancer molecular diagnostics: just biomarker discovery tools or future bedside clinical assays?
    Ross JS
    Expert Rev Mol Diagn; 2005 Nov; 5(6):837-8. PubMed ID: 16255622
    [No Abstract]   [Full Text] [Related]  

  • 27. Farnesyl transferase inhibitors.
    Li T; Sparano JA
    Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
    [No Abstract]   [Full Text] [Related]  

  • 28. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives.
    Nannini M; Pantaleo MA; Maleddu A; Astolfi A; Formica S; Biasco G
    Cancer Treat Rev; 2009 May; 35(3):201-9. PubMed ID: 19081199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1.
    Fensterer H; Giehl K; Buchholz M; Ellenrieder V; Buck A; Kestler HA; Adler G; Gierschik P; Gress TM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):224-35. PubMed ID: 14732924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Making sense of microarray data to classify cancer.
    Hanash S; Creighton C
    Pharmacogenomics J; 2003; 3(6):308-11. PubMed ID: 14597962
    [No Abstract]   [Full Text] [Related]  

  • 31. Alterations of metastasis-related genes identified using an oligonucleotide microarray of genistein-treated HCC1395 breast cancer cells.
    Lee WY; Huang SC; Tzeng CC; Chang TL; Hsu KF
    Nutr Cancer; 2007; 58(2):239-46. PubMed ID: 17640171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols.
    De Angelis PM; Kravik KL; Tunheim SH; Haug T; Reichelt WH
    Mol Cancer; 2004 Apr; 3():11. PubMed ID: 15109396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer.
    Stoss O; Werther M; Zielinski D; Middel P; Jost N; Rüschoff J; Henkel T; Albers P
    Prostate Cancer Prostatic Dis; 2008; 11(2):166-72. PubMed ID: 17646850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discussion of the applicability of microarrays: profiling of leukemias.
    Haferlach T; Bacher U; Kohlmann A; Haferlach C
    Methods Mol Biol; 2009; 509():15-33. PubMed ID: 19212712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer gene microarrays pass muster.
    Twombly R
    J Natl Cancer Inst; 2006 Oct; 98(20):1438-40. PubMed ID: 17047189
    [No Abstract]   [Full Text] [Related]  

  • 38. Implications of micro-RNA profiling for cancer diagnosis.
    Cummins JM; Velculescu VE
    Oncogene; 2006 Oct; 25(46):6220-7. PubMed ID: 17028602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrative analysis of the cancer transcriptome.
    Rhodes DR; Chinnaiyan AM
    Nat Genet; 2005 Jun; 37 Suppl():S31-7. PubMed ID: 15920528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression-driven diagnostics and pharmacogenomics in cancer.
    Wang Y
    Curr Opin Mol Ther; 2005 Jun; 7(3):246-50. PubMed ID: 15977422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.